Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.04
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-3.9M · quality 66.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-23.3%
↓Gross Margin
38.7%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.6%
FCF CAGR
—
FCF margin
-40.7%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.9M · net income $-4.0M · FCF $-2.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.9M | $4.9M | $4.8M | $3.9M | $2.3M |
| Net Income | $-4.0M | $-4.0M | $-7.6M | $-5.4M | $-14.4M |
| EBITDA | $-3.4M | $-3.4M | $-6.6M | $-5.3M | $-14.4M |
| EPS | -0.01 | -0.01 | -0.02 | -0.01 | -0.04 |
| Gross Margin | 38.7% | 38.7% | 42.5% | 43.2% | 26.6% |
| Operating Margin | -85.2% | -85.2% | -130.2% | -125.4% | -408.9% |
| Net Margin | -81.8% | -81.8% | -160.5% | -136.7% | -617.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.09 | 0.07 | 0.05 |
| Current Ratio | 4.56 | 4.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.0M | $-2.0M | $-3.9M | $-6.5M | $-5.3M |
| Returns | |||||
| ROE | -23.3% | -23.3% | -38.0% | -20.7% | -50.5% |
| Valuation | |||||
| P/B | 0.92 | 0.92 | 1.28 | 1.43 | 1.30 |
| Growth & Yield | |||||
| Revenue Growth | 4.0% | 4.0% | 20.3% | 69.8% | — |
| EPS Growth | 50.0% | 50.0% | -100.0% | 75.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+33.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.01
Residual
+33.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.